About Us
Leadership
Our leadership team has deep scientific and clinical expertise in fibrosis and oncology, a clear commercial vision, and a track record in raising finance and bringing therapies into the clinic.
By harnessing the insights generated through our proprietary human extracellular matrix (ECM) platform, we aim to realise our vision to develop life-changing therapeutics and create a healthier future for patients with life-threatening fibrotic diseases and cancers.
Giuseppe Mazza, PhD
Chief Executive Officer and Co-Founder
Dr Giuseppe Mazza
Chief Executive Officer and Co-Founder
Professor Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.
Engitix was established to build on and commercialise Giuseppe’s pioneering research which resulted in a proprietary human extracellular matrix ECM drug discovery platform. His foundational/initial research was carried out in the laboratory of co-founder, Professor Massimo Pinzani at the Institute for Liver and Digestive Health (ILDH), Division of Medicine, University College London (UCL).
As CEO, Giuseppe has led the company through significant growth including several rounds of financing and secured significant partnerships with Dompei, Takeda and Morphic, as well as establishing new cutting-edge bespoke laboratories and offices at WestWorks, White Park, London.
Previously, Giuseppe was a Post-Doctoral Fellow at the UCL ILDH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. He received his PhD in Tissue Engineering and Organ Regeneration from UCL. He still maintains an affiliation with UCL as Honorary Associate Professor. Giuseppe also served as a Director R&D at Promethera Bioscience from 2015 to 2017.
He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.
David Dally
Chief Financial Officer
David Dally
Chief Financial Officer
David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018, having initially worked for the company as a consultant from 2016.
David has 30 years' experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.
David is an experienced executive having held the position of CEO at MerLion Pharmaceuticals from 2013 to 2018, before which he was CFO from 2007.
During his career, David has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.
David is a chartered accountant and holds a MA in Geography from the University of Cambridge.
Chris Stevenson, PhD
Chief Scientific Officer
Chris Stevenson, PhD
Chief Scientific Officer
Christopher (Chris) Stevenson joined Engitix in September 2023 as Chief Scientific Officer.
He has a strong track record of driving innovation and developing talented teams to propel science into novel therapeutic and diagnostic solutions for patients. Chris is responsible for leading Engitix’ scientific and translational strategy, which is focused on advancing a portfolio of novel therapies towards IND-enabling studies and eventually trials in patients with fibrotic diseases and solid tumours. He is also leading the company’s R&D Pharma partnerships centred on its novel platform technologies.
He joined Engitix from Johnson & Johnson, where he most recently served as Vice President, Global Head of Pharmaceutical Sciences for Interventional Oncology. In this role he was responsible for building a team to support discovery through early development programmes and delivering a portfolio of clinical-stage assets, which included multiple cancer immunotherapies and the licensing of NBTXR3 from Nanobiotix.
Prior to this role, Chris headed discovery and translational biology units at Respivert, Novartis and Roche. Over his career, Chris has led the discovery or contributed to the development of over 10 drug candidates aiming to treat fibrosis, inflammation or cancers, as well as authoring over 60 peer reviewed papers and patents.
He received his Doctorate and Bachelor of Science degrees from the University of California, Santa Barbara, USA.
Alan Holmes, PhD
Vice President, Fibrosis
Alan Holmes
Vice President, Fibrosis
Alan Holmes joined Engitix in 2021.
As VP of Fibrosis, Alan leads the fibrosis partnering and internal drug discovery programmes focusing on GI diseases.
He brings over 15 years’ experience gained in working across senior roles in the pharmaceutical industry.
Alan joined Engitix from UCB where he was Director, Drug Target Identification. Before this, he was Director within GSK’s Pulmonary Vascular Injury and Fibrosis DPU. Between 2011 and 2017 he worked at UCL, latterly as Head of Biology in the Drug Discovery, Translational Research Office and previously as a Group leader and Arthritis Research UK fellow in tissue remodelling and fibrosis. Prior to this, Alan was group leader at Novartis.
Alan has published over 30 peer reviewed papers and book chapters and maintains a strong academic interest in the mechanisms that drive the development of chronic diseases. He is currently honouree Professor of the Division of Medicine, at University College London.
He received his PhD from University College London (UCL).
Matt Edwards, PhD
SVP Discovery
Matt Edwards, PhD
SVP Discovery
Dr. Edwards is a seasoned drug discovery leader with extensive industry experience. He has developed six clinically-enabled novel therapeutics and has deep immunology and oncology domain expertise. He joins Engitix from Johnson & Johnson, where he was the Global Head of Discovery and Translational Sciences for Interventional Oncology. In this role, he developed a portfolio of immuno-oncology assets primarily designed to be delivered intra-tumorally, which included low molecular weight drugs, therapeutic antibodies and RNA therapeutics. Prior to this, further industrial drug discovery experience included leadership positions at Novartis, and GSK in the respiratory and immunology therapeutics areas.
Emma Huang , PhD
VP Data Sciences
Emma Huang, PhD
VP Data Sciences
Dr. Huang brings to Engitix a strong track record of identifying and executing on transformative opportunities harnessing data science to accelerate the development of novel therapies and solutions for patients. She joinsEngitix from Johnson & Johnson, where she served as Head of Data Sciences for Interventional Oncology. In this role, she shaped and built key data science capabilities including the data, analytics, platforms, and partnerships necessary to support discovery and translational biomarker efforts.
With over 40 peer reviewed papers, and a career spanning academia, government, and industry, Emma has consistently demonstrated her commitment to scientific advancement and collaboration through roles such as Deputy Chair of the MRC Population & Systems Medicine Board. She holds a Ph.D. in Biostatistics from the University of North Carolina-Chapel Hill, and a B.S. in Mathematics from Caltech.
Amélie Fortin
Senior Director, People and Culture
Amélie Fortin
Senior Director, People and Culture
Amelie Fortin joined Engitix in 2022.
Amelie is an experienced, People and Culture Leader with a strong ability to design and foster purpose-driven, high-performing, and collaborative cultures.
As People and Culture Director at Engitx, Amelie is combining her pro-active approach with strategic and operational expertise to build a diverse team that will enable Engitix to achieve its ambition of creating a healthier future for patients with life-threatening diseases.
Prior to Engitix, she has led people agendas internationally, within the UK, EMEA, USA and APAC regions and has experience across multiple industries including Deep tech, Fintech and Logistics.
Amelie received a Business Administration degree from the Université du Québec à Montréal (UQAM), Canada.
Interests
Outside of work, Amelie enjoys exploring London on foot with her toy poodle Louis.
Andy Roland-Price
Finance Director
Andy Roland-Price
Finance Director
Andy joins us from Purespring Therapeutics, a VC-backed biotech developing gene therapies to treat chronic kidney diseases. He also supports Forcefield Therapeutics, a seed-stage biotech from the same VC portfolio that is developing cardio-protectant proteins. Prior to Purespring Andy was at Imperial College, a research-led STEM university building a new Innovation campus here at White City.
